Expanded Access Policy

Ophirex, Inc., is dedicated to addressing the medical needs associated with snakebite and other diseases and conditions with related mechanisms of illness and injury.

As a registered Public Benefit Corporation, our mission is to make a positive impact on patient and public health, by providing affordable, easy-to-use, safe antidotes. Consistent with our mission, Ophirex is currently conducting the clinical trials necessary to gain regulatory approvals that could make our medicines for snakebite envenoming available as quickly and responsibly as possible.

Expanded Access programs are sometimes used to provide treatment with an investigational product to patients with a serious or life-threatening illness or condition for which there are no comparable or satisfactory alternative treatments available, and who are not eligible for a clinical trial.

Currently, Ophirex does not have an expanded access program for our developmental clinical drug products. We will periodically assess the eligibility requirements and criteria for such a program, with the goal of offering expanded access at the appropriate future juncture in our development path.

As we advance toward broadly providing therapeutics intended to counteract acute toxicity from snakebite envenoming, we are extremely grateful for our collaborations with gifted clinical investigators and for the participation of forward-looking patients. With their support, we hope to make rapid progress toward reaching all patients who could potentially be helped by our treatments.

This page was last modified on March 15, 2022.